Both in adenomas and adenocarcinomas, the observed ACKR2 downregulation resulted from changes in expression in neoplastic tissue while receptor expression in normal mucosa remained relatively stable at subsequent steps of adenoma-adenocarcinoma sequence. This evidence concerns the gene ACKR2 and adenocarcinoma.